Company: ABBV
Filing Date: 2025-04-03
Form Type: 8-K
Source: 0001551152-25-000023
Chunk: 0

Company: AbbVie Inc.
Filing Date: 2025-04-03
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02 Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are expected to include acquired IPR& D and milestones expense of $248 million on a pre-tax basis, representing an unfavorable impact of $0.13 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR& D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR& D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on January 31, 2025 excluded the impact of acquired IPR& D and milestones expense that may be incurred in 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of first quarter 2025 acquired IPR& D and milestones expense, is $11.99 - $12.19. AbbVie’s first quarter 2025 adjusted diluted earnings per share guidance range, including the impact of first quarter 2025 acquired IPR& D and milestones expense, is $2.34 - $2.38. This guidance does not reflect the impact related to AbbVie and Gubra’s licensing agreement to develop GUB014295, as that transaction closed after the first quarter of 2025.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR& D and milestones expense incurred during the first quarter of 2025.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

Forward-Looking Statements

Some statements in this